Flunixin Meglumine
We are a manufacturer based in China. We specialize in providing high-quality Flunixin Meglumine for industrial clients across various sectors. Whether you need chemicals consultation or technical support, our team is here to help.
Category：Chemical Additives MOQ:100KG Shipped directly from China
Introduction
Flunisine meglumine, a veterinary drug, can relieve inflammation and pain caused by abnormal muscle, relieve internal colic of horses, and treat diarrhea, trembling, colitis, respiratory and other system diseases of foals.,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Product Overview
Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID) derived from nicotinic acid, primarily used in veterinary medicine for its potent analgesic, anti-inflammatory, and antipyretic effects. It is commonly administered to horses, cattle, and swine for pain and fever management.
Basic Physicochemical Properties
| Property | Specification | Test Method |
|---|---|---|
| Chemical Name | 2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]nicotinic acid compound with 1-deoxy-1-(methylamino)-D-glucitol | IUPAC nomenclature |
| Molecular Formula | C₁₄H₁₁F₃N₂O₂ · C₇H₁₇NO₅ | Elemental analysis |
| Molecular Weight | 492.48 g/mol (salt form) | Mass spectrometry |
| Appearance | White to off-white crystalline powder | Visual inspection |
| Solubility (25°C) | Freely soluble in water (>100 mg/mL) | USP <911> |
| Melting Point | 150–155°C (decomposes) | DSC analysis |
Pharmacological Profile
| Parameter | Value/Description | Reference Standard |
|---|---|---|
| Mechanism of Action | Non-selective COX inhibitor | FDA-CVM guidelines |
| Bioavailability | >80% (IV/IM in horses) | Veterinary PK studies |
| Half-life (t₁/₂) | 1.5–3.5 hours (species-dependent) | Clinical data |
| Protein Binding | >90% | In vitro studies |
| Excretion | Renal (60–70% unchanged) | EMA veterinary reports |
Veterinary Applications & Dosage
| Species | Indication | Dosage Regimen |
|---|---|---|
| Horses | Musculoskeletal pain, colic | 1.1 mg/kg IV/IM q24h (max 5 days) |
| Cattle | Acute inflammation, fever | 2.2 mg/kg IV/IM single dose |
| Swine | Postoperative pain | 2.2 mg/kg IM q24h (max 3 days) |
Regulatory & Safety Data
| Parameter | Specification |
|---|---|
| Human use status | Not approved (veterinary-only) |
| Withdrawal periods | Cattle: 4 days (meat), 36h (milk) |
| Major adverse effects | GI ulcers, renal toxicity |
| Pregnancy category | Use with caution (avoid late gestation) |
| Environmental impact | Biodegradable (low bioaccumulation) |
Storage & Handling
| Parameter | Requirement |
|---|---|
| Storage conditions | 15–30°C in original container |
| Shelf life | 36 months (unopened) |
| Light sensitivity | Protect from light |
| Packaging | 100mL sterile vials (50mg/mL) |
| Disposal | Incineration or hazardous waste facility |
Conclusion
Flunixin meglumine is a first-line veterinary NSAID for acute pain and inflammation management, offering rapid onset and reliable efficacy. Strict adherence to species-specific dosing and withdrawal periods is essential to ensure food safety.
20+ years export experience. If you're ready to take the next step or Request Free Samples, Leave your message below and we’ll reply soon.
Inquiry
Factory & Shipment
